Vanadyl Treatment Normalizes Submandibular Salivary Gland Insulin-Like Immunoreactivity in Streptozotocin-Diabetic Rats

D. Deville de Périère; P. Poucheret; J.-C. Egea; R. Gross; P. Masiello; G. Cros; J. J. Serrano; G. Ribes

doi:10.1055/s-2007-978855

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 1998; 30(3): 150-152
DOI: 10.1055/s-2007-978855

Originals Clinical

Vanadyl Treatment Normalizes Submandibular Salivary Gland Insulin-Like Immunoreactivity in Streptozotocin-Diabetic Rats

D. Deville de Périère¹ , P. Poucheret² , J.-C. Egea¹ , R. Gross³ , P. Masiello¹ ^,*, G. Cros² , J. J. Serrano² , G. Ribes³

¹Laboratoire de Physiologie. Faculté d'Odontologie. B. P. 4305 Montpellier, France
²Laboratoire de Pharmacologie. Faculté de Pharmacie. 34060 - Montpellier Cedex 01, France
³Laboratoire de Pharmacologie. Faculté de Médecine. UMR - CNRS 9921, 34060 - Montpellier Cedex 01, France

* on leave from Istituto Patologia Generale, University of Pisa, Italy

Abstract

PDF Download

Rat submandibular salivary glands (SSG) contain a compound displaying insulin-like immunoreactivity (ILI) and various biological activities of insulin. As SSG ILI levels were reported to be increased in streptozotocin (STZ)-induced diabetes but not normalized by a two-week insulin treatment, we decided to check whether another antidiabetic treatment, vanadyl sulphate (VOSO₄), was able to regulate SSG ILI concentration. A short term (8 days) i.p. VOSO₄ treatment (total dose = 1.3 mmol/kg) of rats made diabetic 8 days earlier by a single i.v. injection of STZ (60 mg/kg BW) was able to induce a long-term (4 weeks) correction of hyperglycemia while weight gain was re-established. In untreated diabetic animals (≈ - 25%) and increased (≈ + 175%) as compared to normal rats. Both parameters were normalized in VOSO₄-treated diabetic rats.

Key words

Insulin-like Immunoreactivity - Submandibular Salivary Gland - Diabetes - Rat - Vanadyl

PDF (258 kb)